9.50Open9.50Pre Close0 Volume0 Open Interest12.50Strike Price0.00Turnover0.00%IV22.22%PremiumOct 18, 2024Expiry Date5.50Intrinsic Value100Multiplier0DDays to Expiry4.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma3.10Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Kura Oncology Stock Discussion
Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology | KURA Stock News
$Kura Oncology (KURA.US)$
No comment yet